Brighton Jones LLC Sells 1,739 Shares of Celgene Co. (CELG)

Brighton Jones LLC decreased its position in shares of Celgene Co. (NASDAQ:CELG) by 23.3% during the first quarter, HoldingsChannel reports. The institutional investor owned 5,740 shares of the biopharmaceutical company’s stock after selling 1,739 shares during the quarter. Brighton Jones LLC’s holdings in Celgene were worth $541,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Capital Management Corp VA purchased a new stake in shares of Celgene during the 1st quarter worth $10,955,000. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp grew its holdings in Celgene by 36.9% during the fourth quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 342,301 shares of the biopharmaceutical company’s stock worth $21,938,000 after acquiring an additional 92,209 shares during the period. Tibra Equities Europe Ltd acquired a new stake in Celgene during the first quarter worth about $6,396,000. Bell Asset Management Ltd grew its holdings in Celgene by 13.7% during the fourth quarter. Bell Asset Management Ltd now owns 78,822 shares of the biopharmaceutical company’s stock worth $5,052,000 after acquiring an additional 9,525 shares during the period. Finally, Global Trust Asset Management LLC grew its holdings in Celgene by 212.3% during the first quarter. Global Trust Asset Management LLC now owns 4,557 shares of the biopharmaceutical company’s stock worth $430,000 after acquiring an additional 3,098 shares during the period. 74.47% of the stock is currently owned by institutional investors and hedge funds.

In other news, Director James J. Loughlin sold 23,466 shares of Celgene stock in a transaction on Thursday, February 7th. The stock was sold at an average price of $87.29, for a total value of $2,048,347.14. Following the completion of the sale, the director now directly owns 62,102 shares of the company’s stock, valued at $5,420,883.58. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Ernest Mario acquired 2,000 shares of the company’s stock in a transaction dated Tuesday, February 12th. The stock was purchased at an average cost of $89.99 per share, with a total value of $179,980.00. The disclosure for this purchase can be found here. 0.39% of the stock is owned by insiders.

NASDAQ:CELG opened at $94.22 on Monday. Celgene Co. has a 52 week low of $58.59 and a 52 week high of $95.44. The company has a current ratio of 2.23, a quick ratio of 2.12 and a debt-to-equity ratio of 3.21. The firm has a market capitalization of $66.18 billion, a price-to-earnings ratio of 12.38, a price-to-earnings-growth ratio of 0.43 and a beta of 1.71.

Celgene (NASDAQ:CELG) last posted its earnings results on Thursday, April 25th. The biopharmaceutical company reported $2.55 EPS for the quarter, beating the Zacks’ consensus estimate of $2.45 by $0.10. Celgene had a return on equity of 125.23% and a net margin of 30.10%. The company had revenue of $4.03 billion for the quarter, compared to the consensus estimate of $4.01 billion. During the same quarter in the previous year, the business earned $2.05 earnings per share. The company’s revenue for the quarter was up 13.8% on a year-over-year basis. On average, research analysts predict that Celgene Co. will post 10.02 EPS for the current fiscal year.

Several research firms recently commented on CELG. Zacks Investment Research lowered Celgene from a “buy” rating to a “hold” rating in a report on Wednesday, April 3rd. ValuEngine lowered Celgene from a “hold” rating to a “sell” rating in a report on Wednesday, April 24th. BidaskClub lowered Celgene from a “hold” rating to a “sell” rating in a report on Thursday. Mizuho set a $103.00 price objective on Celgene and gave the company a “buy” rating in a report on Friday, April 5th. Finally, UBS Group lowered Celgene from a “buy” rating to a “neutral” rating and raised their price objective for the company from $94.00 to $102.00 in a report on Monday, April 1st. Two analysts have rated the stock with a sell rating, seventeen have assigned a hold rating and nine have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $99.41.

WARNING: This piece was originally posted by Transcript Daily and is owned by of Transcript Daily. If you are accessing this piece on another site, it was stolen and republished in violation of international copyright & trademark laws. The legal version of this piece can be viewed at https://transcriptdaily.com/2019/04/29/brighton-jones-llc-sells-1739-shares-of-celgene-co-celg.html.

Celgene Profile

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Featured Story: How the Consumer Price Index (CPI) is calculated?

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.